FDA Rejects Moderna’s Flu Vaccine Due to Comparator Choice | Ars Technica

The Food and Drug Administration (FDA) has refused to review Moderna’s application for mRNA-1010, its experimental mRNA-based flu vaccine, the company announced on February 10, 2026. The decision, delivered in a “refusal-to-file” letter, centers not on safety or efficacy data, but on the design of the clinical trial used to support the application. This setback highlights a growing tension between Moderna and the FDA, particularly under the leadership of Health Secretary Robert F. Kennedy Jr., and raises questions about the future of mRNA vaccine development in the United States.

The core of the FDA’s objection, as articulated by Dr. Vinay Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER), is that Moderna’s trial did not utilize the “best-available standard of care” as a comparator. Specifically, the trial compared mRNA-1010 to Fluarix, a standard-dose seasonal influenza shot already approved by the FDA. Prasad’s letter states the trial was therefore “not adequate and well-controlled.”

This reasoning has drawn criticism from Moderna, which argues that the FDA’s position is inconsistent with prior feedback received in 2024 and 2025. The company maintains that using an FDA-approved vaccine as a benchmark was previously discussed and agreed upon with CBER before the trial commenced. “It should not be controversial to conduct a comprehensive review of a flu vaccine submission that uses an FDA-approved vaccine as a comparator in a study that was discussed and agreed on with CBER prior to starting,” stated Moderna CEO Stéphane Bancel in a press release. The company has requested a meeting with the FDA to clarify the agency’s concerns and determine a path forward.

The implications of this decision extend beyond Moderna’s immediate prospects for an mRNA flu vaccine. MRNA technology, which gained prominence during the COVID-19 pandemic with the rapid development and deployment of highly effective vaccines, offers potential advantages over traditional vaccine manufacturing methods. These include faster development timelines and greater flexibility in responding to evolving viral strains. A roadblock to approval for an mRNA-based flu vaccine could stifle innovation in this promising field.

Moderna’s clinical trial data, released last year, indicated that mRNA-1010 was 26.6% more effective than the standard flu shot used as a comparator. While the FDA has not disputed these efficacy findings, the agency’s focus on the trial design suggests a heightened level of scrutiny for mRNA vaccines. This increased scrutiny aligns with a broader trend observed since Robert F. Kennedy Jr. Assumed the role of Health Secretary. Reports indicate Kennedy Jr. Has been critical of mRNA technology and has overseen the cancellation of millions of dollars in related research projects.

The FDA’s decision is particularly noteworthy given that mRNA-1010 has already been accepted for review by regulatory bodies in other major markets, including the European Union, Canada, and Australia. This suggests that the standards for vaccine approval may be diverging internationally, potentially creating challenges for companies seeking to market innovative vaccines globally.

The controversy also raises questions about the evolving definition of “standard of care” in vaccine clinical trials. Traditionally, a comparator vaccine serves as a baseline to demonstrate the superiority of a new vaccine. However, the FDA’s insistence on the “best-available standard of care” implies a higher threshold, potentially requiring comparison to more recently developed or more effective vaccines, even if those vaccines are not yet widely available or routinely used. This could significantly increase the cost and complexity of vaccine development.

The situation is further complicated by the fact that the FDA did not identify any specific safety concerns with mRNA-1010. This suggests that the agency’s objection is purely procedural, based on the trial design rather than the vaccine’s inherent properties. However, the lack of transparency surrounding the FDA’s reasoning has fueled criticism from Moderna and raised concerns about the agency’s commitment to fostering innovation in mRNA vaccine technology.

Looking ahead, Moderna is actively seeking clarification from the FDA and hopes to resolve the issues preventing a full review of its application. The company emphasizes the importance of providing Americans with access to domestically produced, cutting-edge vaccines. The outcome of this dispute will likely have significant ramifications for the future of mRNA vaccine development and the broader landscape of influenza prevention.